BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19714456)

  • 1. Malignant hyperthermia susceptibility in a patient with mitochondrial disorder.
    Finsterer J; Michalek-Sauberer A; Höftberger R
    Metab Brain Dis; 2009 Sep; 24(3):501-6. PubMed ID: 19714456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.
    Serfas KD; Bose D; Patel L; Wrogemann K; Phillips MS; MacLennan DH; Greenberg CR
    Anesthesiology; 1996 Feb; 84(2):322-9. PubMed ID: 8602662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of the caffeine-halothane contracture test for the diagnosis of malignant hyperthermia in Brazil.
    Sudo RT; Cunha LB; Carmo PL; Matos AR; Trachez MM; Cardoso LA; Aguiar MI; Abreu AV; Zapata-Sudo G
    Braz J Med Biol Res; 2010 Jun; 43(6):549-56. PubMed ID: 20464345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.
    Ording H; Brancadoro V; Cozzolino S; Ellis FR; Glauber V; Gonano EF; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Kozak-Ribbens G; Kress H; Krivosic-Horber R; Lehmann-Horn F; Mortier W; Nivoche Y; Ranklev-Twetman E; Sigurdsson S; Snoeck M; Stieglitz P; Tegazzin V; Urwyler A; Wappler F
    Acta Anaesthesiol Scand; 1997 Sep; 41(8):955-66. PubMed ID: 9311391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of general anesthesia in patients previously tested negative for malignant hyperthermia susceptibility.
    Allen GC; Rosenberg H; Fletcher JE
    Anesthesiology; 1990 Apr; 72(4):619-22. PubMed ID: 2321777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors of the contracture test for diagnosing malignant hyperthermia in a Brazilian population sample: a retrospective observational study.
    de Mello JM; Andrade PV; Santos JM; Oliveira ASB; Vainzof M; do Amaral JLG; Almeida da Silva HC
    Braz J Anesthesiol; 2023; 73(2):145-152. PubMed ID: 35835312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contractures in skeletal muscle of malignant hyperthermia susceptible patients after in vitro exposure to sevoflurane.
    Snoeck MM; Gielen MJ; Tangerman A; van Egmond J; Dirksen R
    Acta Anaesthesiol Scand; 2000 Mar; 44(3):334-7. PubMed ID: 10714850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inositol 1,4,5-trisphosphate synthesis in mononuclear white blood cells of malignant hyperthermia-susceptible and normal human beings, following in vitro exposure to halothane, caffeine and ryanodine.
    Martens U; Krause T; Scholz J; Wappler F; Steinrücke K; am Esch JS
    Eur J Anaesthesiol; 2000 Jun; 17(6):364-72. PubMed ID: 10928436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of cocaine on the contracture response to 1% halothane in patients undergoing diagnostic muscle biopsy for malignant hyperthermia.
    Sato N; Brum JM; Mitsumoto H; DeBoer GE
    Can J Anaesth; 1995 Feb; 42(2):158-62. PubMed ID: 7720160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine: a comparative investigation in malignant hyperthermia.
    Bendahan D; Guis S; Monnier N; Kozak-Ribbens G; Lunardi J; Ghattas B; Mattei JP; Cozzone PJ
    Acta Anaesthesiol Scand; 2004 Sep; 48(8):1019-27. PubMed ID: 15315621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility.
    Wappler F; Anetseder M; Baur CP; Censier K; Doetsch S; Felleiter P; Fiege M; Fricker R; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Hopkins PM; Klingler W; Lehmann-Horn F; Nivoche Y; Tegazzin V; Tzanova I; Urwyler A; Weisshorn R; Schulte am Esch J
    Eur J Anaesthesiol; 2003 Jul; 20(7):528-36. PubMed ID: 12884985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of caffeine, halothane, and 4-chloro-m-cresol on skeletal muscle lactate and pyruvate in malignant hyperthermia-susceptible and normal swine as assessed by microdialysis.
    Bina S; Cowan G; Karaian J; Muldoon S; Mongan P; Bünger R
    Anesthesiology; 2006 Jan; 104(1):90-100. PubMed ID: 16394695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar susceptibility to halothane, caffeine and ryanodine in vitro reflects pharmacogenetic variability of malignant hyperthermia.
    Ginz HF; Girard T; Censier K; Urwyler A
    Eur J Anaesthesiol; 2004 Feb; 21(2):151-7. PubMed ID: 14977348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro contracture testing for susceptibility to malignant hyperthermia: can halothane be replaced?
    Metterlein T; Schuster F; Kranke P; Roewer N; Anetseder M
    Eur J Anaesthesiol; 2011 Apr; 28(4):251-5. PubMed ID: 20827211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels.
    Weglinski MR; Wedel DJ; Engel AG
    Anesth Analg; 1997 May; 84(5):1038-41. PubMed ID: 9141928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muscle biopsy for malignant hyperthermia screening in children.
    Ummenhofer W; Roesslein R; Sutter PM; Moser N; Kern C; Urwyler A
    Eur J Pediatr Surg; 1997 Oct; 7(5):259-62. PubMed ID: 9402480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Masseter muscle rigidity and malignant hyperthermia susceptibility in pediatric patients. An update on management and diagnosis.
    O'Flynn RP; Shutack JG; Rosenberg H; Fletcher JE
    Anesthesiology; 1994 Jun; 80(6):1228-33. PubMed ID: 8010468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of greyhound susceptibility to malignant hyperthermia using halothane-succinylcholine anesthesia and caffeine-halothane muscle contractures.
    Cosgrove SB; Eisele PH; Martucci RW; Gronert GA
    Lab Anim Sci; 1992 Oct; 42(5):482-5. PubMed ID: 1460848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of European and North American malignant hyperthermia diagnostic protocol outcomes for use in genetic studies.
    Fletcher JE; Rosenberg H; Aggarwal M
    Anesthesiology; 1999 Mar; 90(3):654-61. PubMed ID: 10078664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ryanodine contracture test may help diagnose susceptibility to malignant hyperthermia.
    Reuter DA; Anetseder M; Müller R; Roewer N; Hartung EJ
    Can J Anaesth; 2003; 50(7):643-8. PubMed ID: 12944436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.